Todays Report: Today, Protagonist Therapeutics Inc (PTGX) Lowered by The Zacks Investment Research to “Sell”

Today, Protagonist Therapeutics Inc (PTGX) Lowered by The Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) from a hold rating to a sell rating in a report released on Thursday.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

A number of other equities analysts have also recently issued reports on the stock. BMO Capital Markets reiterated an outperform rating and set a $34.00 price objective (up from $21.00) on shares of Protagonist Therapeutics in a research report on Friday, November 18th. Leerink Swann assumed coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an outperform rating and a $17.00 price objective for the company. Finally, Barclays PLC assumed coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an overweight rating and a $18.00 price objective for the company.

Shares of Protagonist Therapeutics (NASDAQ:PTGX) opened at 25.12 on Thursday. Protagonist Therapeutics has a one year low of $10.02 and a one year high of $25.50. The firm’s market capitalization is $419.86 million. The company’s 50 day moving average is $21.82 and its 200-day moving average is $17.93.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by $0.29. During the same period last year, the business posted ($12.79) EPS.

Large investors have recently bought and sold shares of the company. Credit Suisse AG acquired a new stake in Protagonist Therapeutics during the third quarter worth $358,000. BVF Inc. IL acquired a new stake in Protagonist Therapeutics during the third quarter worth $7,924,000. RA Capital Management LLC acquired a new stake in Protagonist Therapeutics during the third quarter worth $15,941,000. Adage Capital Partners GP L.L.C. acquired a new stake in Protagonist Therapeutics during the third quarter worth $33,408,000. Finally, Spark Investment Management LLC acquired a new stake in Protagonist Therapeutics during the third quarter worth $889,000.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

Related posts

Leave a Comment